Literature DB >> 16420061

Dopamine/serotonin receptor ligands. 10: SAR Studies on azecine-type dopamine receptor ligands by functional screening at human cloned D1, D2L, and D5 receptors with a microplate reader based calcium assay lead to a novel potent D1/D5 selective antagonist.

Barbara Hoefgen1, Michael Decker, Patrick Mohr, Astrid M Schramm, Sherif A F Rostom, Hussein El-Subbagh, Peter M Schweikert, Dirk R Rudolf, Matthias U Kassack, Jochen Lehmann.   

Abstract

On the basis of the benz[d]indolo[2,3-g]azecine derivative 1 (LE300), structure-activity relations were investigated in order to identify the pharmacophore in this new class of ligands. Various structural modifications were performed and the inhibitory activities at human cloned D(1), D(2L), and D(5) receptors were measured by using a simple fluorescence microplate reader based calcium assay. Subsequently, the affinities of active compounds were estimated by radioligand binding experiments. Deleting one of the aromatic rings as well as replacing it by a phenyl moiety abolishes the inhibitory activities almost completely. Contraction of the 10-membered central ring decreases them significantly. The replacement of indole by thiophene or N-methylpyrrole reduces the inhibitory activity, whereas replacing the indole by benzene increases it. Finally, the hydroxylated dibenz[d,g]azecine derivative 11d (LE404) was found to be more active than the lead 1 in the functional calcium assay as well as in radioligand displacement experiments.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16420061     DOI: 10.1021/jm050846j

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  1 in total

1.  Dibenzazecine compounds with a novel dopamine/5HT2A receptor profile and 3D-QSAR analysis.

Authors:  Alexandra Hamacher; Mathias Weigt; Michael Wiese; Barbara Hoefgen; Jochen Lehmann; Matthias U Kassack
Journal:  BMC Pharmacol       Date:  2006-09-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.